NeRRe Therapeutics Ltd, a 2012 spin-out of GlaxoSmithKline Plc, has raised £23 million in an oversubscribed Series B financing round to advance its portfolio of neurokinin receptor antagonists. The lead product is being developed for a chronic respiratory condition.
